Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the non hodgkin lymphoma (nhl) market grown over the years?

The market size of Non-Hodgkin Lymphoma (NHL) has witnessed robust expansion in the past few years. The market which was valued at $10.11 billion in 2024 is set to ascend to $11.01 billion in 2025, indicating a Compound Annual Growth Rate (CAGR) of 8.9%. The past period’s growth can be ascribed to a surge in NHL cases, innovation in diagnosis, chemotherapy, and immunotherapy, expansions in clinical research and drug formulation, along with a rise in patient survival rates.

What Is the forecasted market size and growth rate for the non hodgkin lymphoma (nhl) market?

Expectations are high for robust expansion in the non hodgkin lymphoma (NHL) market in the coming years. The market is projected to escalate to “$15.42 billion in 2029 with a compound annual growth rate (CAGR) of 8.8%. The forecasted growth can be credited to a rise in the elderly population, progress in targeted therapies, advances in immunotherapy, precision medicine initiatives, increased awareness, and early detection. Key trends in the forecast period include the emergence of biosimilars, the implementation of next-generation sequencing, the utilization of car-t cell therapies, novel chemotherapy agents, and real-world evidence and outcomes research.

Get your non hodgkin lymphoma (nhl) market report here!

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

What are the major factors driving growth in the non hodgkin lymphoma (nhl) market?

The non-Hodgkin lymphoma market is expected to grow owing to the increased occurrence of the disease. Non-Hodgkin lymphoma, a form of cancer that originates in the lymphatic part of the immune system, is increasingly prevalent. This prevalence signifies the count of individuals who are diagnosed with or living with this disease at a given time. Treatments for non-Hodgkin lymphoma offer improved prospects for those already afflicted by concentrating on and managing the cancerous cells. For example, data from the American Cancer Society reveal that non-Hodgkin lymphoma represents 4% of all cancers and it’s predicted that around 80,550 Americans, including 44,880 men and 35,670 women, will be affected by it in 2023. The society also anticipated that the disease will cause approximately 20,180 fatalities in the same year. Similarly, the Canadian Cancer Society predicted that 11,400 Canadians would be diagnosed with non-Hodgkin lymphoma in 2022, leading to 3,000 deaths. Therefore, the high occurrence of non-Hodgkin lymphoma is a primary driver of its market’s expansion.

What key areas define the segmentation of the global non hodgkin lymphoma (nhl) Market?

The non hodgkin lymphoma (NHL) market covered in this report is segmented –

1) By Type: B-Cell Lymphoma, T-Cell Lymphoma

2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

3) By Route of Administration: Oral, Parenteral, Other Routes of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal B-Cell Lymphoma

2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma (ATLL)

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10676&type=smp

What are the top market players propelling the growth of the non hodgkin lymphoma (nhl) industry?

Major companies operating in the non hodgkin lymphoma (NHL) market include Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Biogen Idec, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

What are the key trends shaping the future of the non hodgkin lymphoma (nhl) market?

Growth in drug development breakthroughs is an emerging key trend seen in the non-Hodgkin lymphoma market. Companies within the non-Hodgkin market are committed to product innovation to cement their market standing. Take, for example, Genentech Inc., an American biotech corporation, which got FDA clearance for Lunsumio, a ground-breaking bispecific antibody for addressing relapsed or unresponsive follicular lymphoma, in December 2022. This antibody introduces a new type of fixed-length immunotherapy for cancer treatment, which is always readily accessible and doesn’t need patients to wait for this immunotherapy treatment. The FDA approval is justified by favorable outcomes from the Lunsumio Phase II GO29781 research for individuals who have been subjected to extensive prior treatments for FL, most notably those who are at high risk of disease progression or have been resistant to previous treatments.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10676

What regions are dominating the non hodgkin lymphoma (nhl) market growth?

North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non-Hodgkin lymphoma (NHL) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Cloud Security Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cloud-security-global-market-report

Hematology Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/hematology-drug-global-market-report

IoT Security Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/iot-security-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: